Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1997 1
1998 4
1999 2
2000 2
2001 4
2002 4
2003 2
2004 5
2005 4
2006 6
2007 7
2008 4
2009 2
2011 3
2012 4
2014 1
2015 1
2016 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16341948

57 results

Results by year

Filters applied: . Clear all
Page 1
Side effects of interferon-alpha therapy.
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Sleijfer S, et al. Pharm World Sci. 2005 Dec;27(6):423-31. doi: 10.1007/s11096-005-1319-7. Pharm World Sci. 2005. PMID: 16341948
[Side effects of interferon alfa].
Berk L, van Gool AR, Bannink M, Kruit WH. Berk L, et al. Ned Tijdschr Geneeskd. 1999 Jul 10;143(28):1461-4. Ned Tijdschr Geneeskd. 1999. PMID: 10443261 Review. Dutch.
Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group. Ogawa E, et al. J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x. J Gastroenterol Hepatol. 2012. PMID: 22098185 Clinical Trial.
Neuropsychiatric side effects of interferon-alfa therapy.
Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Van Gool AR, et al. Pharm World Sci. 2003 Feb;25(1):11-20. doi: 10.1023/a:1022449613907. Pharm World Sci. 2003. PMID: 12661471 Review.
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL; HBV 99-01 Study Group. van Zonneveld M, et al. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71. doi: 10.1111/j.1365-2036.2005.02453.x. Aliment Pharmacol Ther. 2005. PMID: 15854180 Free article. Clinical Trial.
[Alpha-interferon and mental disorders].
Debien C, De Chouly De Lenclave MB, Foutrein P, Bailly D. Debien C, et al. Encephale. 2001 Jul-Aug;27(4):308-17. Encephale. 2001. PMID: 11686052 Review. French.
57 results